ReproCell Stock

ReproCell Equity Turnover

The Equity Turnover of ReproCell (4978.T) as of Sep 4, 2026 is 0.33. In the previous year, Equity Turnover was 0.29 — a change of 13.54% (higher).

Equity Turnover

0.33

YoY

13.54%

Last updated:

Equity Turnover of ReproCell is 2026 0.33 . Equity Turnover of ReproCell was 2025 0.29 . It decreases by 13.54% higher compared to the previous year.

The ReproCell Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
0.15 JPY
Jan 1, 2019
0.15 JPY
Jan 1, 2020
0.20 JPY
Jan 1, 2021
0.24 JPY
Jan 1, 2022
0.31 JPY
Jan 1, 2023
0.39 JPY
Jan 1, 2024
0.29 JPY
Jan 1, 2025
0.33 JPY
The ReproCell Equity Turnover history
YEAREquity TurnoverYoY
0.33+13.54%
0.29-25.11%
0.39+26.50%
0.31+29.01%
0.24+20.46%
0.20+28.80%
0.15+3.86%
0.15-13.16%
0.17+16.34%
0.15+83.35%
0.08-9.81%
0.09—
Access this data via the Eulerpool API
Get Free API Key

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Equity Turnover of ReproCell is 0.33 in 2026.

Equity Turnover of ReproCell changed from 0.29 to 0.33, representing a 13.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover ReproCell since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API
Get Free API Key

Profitability — ReproCell

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — ReproCell